A Study of HRS2543 in Patients With Advanced Tumors

NCT05068856 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped R\&d strategy adjustment

Conditions

Advanced Tumors

Interventions

DRUG: HRS2543

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.